Navigation Links
Clinical Data from NewLink Genetics' HyperAcute Prostate Cancer Immunotherapy Published in Journal of Immunotherapy
Date:12/13/2012

ommercializing novel immunotherapeutic products to improve treatment options for cancer patients. NewLink's portfolio includes biologic and small-molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink's product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens. NewLink's lead product candidate, algenpantucel-L (HyperAcute Pancreas) is being studied in a Phase 3 clinical trial in surgically resected pancreatic cancer patients (under a Special Protocol Assessment with the U.S. FDA) as well as in a separate study in locally advanced pancreatic cancer patients. NewLink has recently launched an adaptive design Phase 2B/3 clinical trial of tergenpumatucel-L (HyperAcute Lung) in patients with non-small cell lung cancer. NewLink is developing indoximod (d-1-methyltryptophan, or D-1MT), a small-molecule, orally bioavailable product candidate from NewLink's proprietary indoleamine-(2, 3)-dioxygenase, or IDO, pathway inhibitor technology. NewLink is studying indoximod in various chemotherapy and immunotherapy combination studies independently and in collaboration with the National Cancer Institute. For more information please visit http://www.linkp.com. Patient information is available at http://www.pancreaticcancer-clinicaltrials.com

Safe Harbor Statement

This press release contains forward-looking statements of NewLink that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan,""target," "pote
'/>"/>

SOURCE NewLink Genetics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
2. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
3. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
4. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
5. Southern Research Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings
6. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
7. New Clinical Endocrinology Guidelines Support Lp-PLA2 Measurement For Risk Assessment of Coronary Artery Disease
8. First Patient Treated in U.S. Clinical Study of Cohera Medicals TissuGlu® Surgical Adhesive
9. Michael J. Fox Foundation-Funded Study Identifies Best Dyskinesia Clinical Rating Scale
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Therapeutics, Inc. (NASDAQ: SRNE ; Sorrento) today announced ... Officer and Executive Vice President. Mr. Singh died suddenly and ... "Sorrento is deeply saddened and shocked by the loss of ... Amar,s family and friends," said Henry Ji , Ph.D., ... Singh joined Sorrento in January 2014 from Synta Pharmaceuticals, where ...
(Date:7/31/2014)... July 31, 2014  ResMed Inc. (NYSE: RMD ... the fiscal year ended June 30, 2014.  Revenue for the ... June 30, 2013 (a 1 percent decrease on a constant ... 20 percent compared to the quarter ended June 30, 2013. ... increase of 22 percent compared to the quarter ended June ...
(Date:7/31/2014)... 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... the quarter ended June 30, 2014. Financial Results ... Revenue Total revenue for the quarter ended June 30, ... quarter ended June 30, 2013 primarily due to IMBRUVICA ® ... Total revenue for the six months ended June 30, ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23
... AT&T * today announced that the Arkansas Department ... mobile flu clinic solution to help the agency more efficiently ... to extend the use of the application to other year-round ... As an important part of its mission to ...
... 2011 Inhibitex, Inc. (Nasdaq: INHX ) today ... shares of its common stock, at a purchase price of ... The net proceeds to Inhibitex from the sale of the ... are expected to be approximately $44 million.  Inhibitex has granted ...
Cached Medicine Technology:Arkansas Department of Health Chooses AT&T to Streamline Delivery of Public Health Programs 2Arkansas Department of Health Chooses AT&T to Streamline Delivery of Public Health Programs 3Arkansas Department of Health Chooses AT&T to Streamline Delivery of Public Health Programs 4Inhibitex Prices $47 Million Public Offering 2Inhibitex Prices $47 Million Public Offering 3
(Date:8/2/2014)... (PRWEB) August 02, 2014 Apervi, ... orchestration platform simplifying data engineering for big data, ... is one of the first Enterprise data engineering ... Spark. Databricks, the company founded by the creators ... as a means to encourage new development on ...
(Date:8/2/2014)... (PRWEB) August 02, 2014 CEDR ... nation's number one provider of customized medical and dental ... major dental-industry conferences this fall. CEDR’s CEO will be ... September and early December. , From September 4-6, CEDR ... Office Managers (AADOM) Dental Managers Conference in San Diego, ...
(Date:8/1/2014)... Recently, iFitDress.com, one of the most famous dress suppliers ... top bridesmaid dresses online. At the moment, all the ... 52% off. According to the company’s senior spokesman, the special ... The company’s stock is limited. Those who are thinking of ... soon as possible. All its products are delicately made by ...
(Date:8/1/2014)... in St. Louis helps explain why brain tumors occur ... than similar tumors in females. For example, glioblastomas, the ... often in males, who suffer greater cognitive impairments than ... researchers found that retinoblastoma protein (RB), a protein known ... male brain cells than in female brain cells. , ...
(Date:8/1/2014)... 2014 Stryker hip lawsuits ( ... 2012 Rejuvenate and ABG II Modular-Neck Hip Stem ... Bergen County Superior Court, Bernstein Liebhard LLP reports. ... Court has issued a Final Amended Stipulated ... hard copy and electronic materials produced by any ...
Breaking Medicine News(10 mins):Health News:Databricks Certifies Apervi Conflux Director TM on Spark, Supercharging the Data to Insight Journey 2Health News:Databricks Certifies Apervi Conflux Director TM on Spark, Supercharging the Data to Insight Journey 3Health News:Nuanced Media Client, CEDR HR Solutions, to Speak at Upcoming Major Dental Conferences 2Health News:Nuanced Media Client, CEDR HR Solutions, to Speak at Upcoming Major Dental Conferences 3Health News:iFitDress.com: Top Bridesmaid Dresses For The Global Customers 2Health News:Study reveals one reason brain tumors are more common in men 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3
... inflammation and loss of cartilage in joints, is likely ... // ,Researchers led by David Felson, a professor ... with symptomatic osteoarthritis of the knee for 30 months. ... the online edition of BBC News. ,The ...
... for capacity Building', Ministry of Health and Family ... Rs. 1.50 crores or actual, whichever is less, ... State Hospitals of towns/cities located on National Highways. ... Road Transport and Highways and Ministry of Health ...
... an amazing figure at the cost of their own health. ... large population is opting for laxative abuse. ,Assumptions about ... which proved that 20% of women who wanted to lose ... students. ,Though these women start with few pills a ...
... 9th of November, urging parents to prevent use of fluoridated ... dentists are concerned about the exposure to fluoride at such ... teeth it might permanently damage them, apart from which it ... cancer boys. ,This advice is not noticed by many ...
... of food poison. Then, fame came as a temporary ... 'miracle poison' and used for an increasing number of ... Mayo Clinic Health Letter covers how this drug works ... ,Botulinum toxin blocks communication between nerves and muscles. Food ...
... the increasing number of children pronounced as juvenile diabetics, it ... such diseases //on their little ones. What used to ... silently attacking children, and it is imperative that parents and ... hand. ,New data from the International Diabetes ...
Cached Medicine News:Health News:Laxatives are Not the Right Option for Losing Weight 2
Stainless steel bone clamp....
Designed for proximal femoral elevation in total hip replacement or in other surgery with a similar need for bone manipulation....
To elevate, dissect, scrape and apply traction to bone and soft tissue....
The AV Plus DX pacing lead is designed for use with the St. Jude Medical Affinity VDR pulse generator. This single-lead pacing system provides reliable pacing therapy with the added benefits of AV sy...
Medicine Products: